FactSet Research Systems (FDS) - FREE Research Report

Laird Joseph E Jr who is Director at FACTSET RESH sold 1,000 shares at $105.64 per share for a total value of $105,640.00 on July 8, 2013. Following this transaction, the Director owned 3,000 shares meaning that the stake was reduced by 25% with the 1,000 share sell-off.

The shares most recently traded at $105.10, up $1.48, or 1.43% since the insider transaction. Historical insider transactions for FactSet Research Systems go as follows:

  • 4-Week # shares sold: 7,624
  • 12-Week # shares sold: 7,624
  • 24-Week # shares sold: 12,574

The average volume for FactSet Research Systems has been 413,400 shares per day over the past 30 days. FactSet Research Systems has a market cap of $4.5 billion and is part of the technology sector and computer software & services industry. Shares are up 17.67% year to date as of the close of trading on Friday.

FactSet Research Systems Inc. provides financial and economic information to investment community worldwide. The stock currently has a dividend yield of 1.36%. The company has a P/E ratio of 23.6. Currently there are 2 analysts that rate FactSet Research Systems a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FDS - FREE

TheStreet Quant Ratings rates FactSet Research Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full FactSet Research Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

If you liked this article you might like

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird

Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Jim Cramer's 'Mad Money' Recap: These Stocks Will Rise, Whatever the Fed Does